Rapid Dose Therapeutics Corp. DOSE
CNSX
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -18.51% | 5.79% | 33.12% | 68.58% | 90.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.51% | 5.79% | 33.12% | 68.58% | 90.94% |
| Cost of Revenue | -13.64% | 13.72% | 56.36% | 106.88% | 135.33% |
| Gross Profit | -23.01% | -1.16% | 15.37% | 42.65% | 62.58% |
| SG&A Expenses | -43.99% | -42.62% | -39.77% | -7.57% | 15.06% |
| Depreciation & Amortization | 28.98% | 73.87% | 112.69% | 13.78% | -25.61% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.19% | -26.84% | -20.90% | 1.63% | 14.84% |
| Operating Income | 44.52% | 48.47% | 47.90% | 25.31% | 12.20% |
| Income Before Tax | 31.12% | 34.15% | 37.24% | 26.79% | 17.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.12% | 34.15% | 37.24% | 26.79% | 17.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.12% | 34.15% | 37.24% | 26.79% | 17.35% |
| EBIT | 44.52% | 48.47% | 47.90% | 25.31% | 12.20% |
| EBITDA | 44.55% | 48.90% | 51.62% | 26.29% | 10.02% |
| EPS Basic | 34.88% | 37.91% | 41.40% | 33.33% | 26.29% |
| Normalized Basic EPS | 34.78% | 37.57% | 41.33% | 25.37% | 17.01% |
| EPS Diluted | 34.88% | 37.91% | 41.40% | 33.33% | 26.29% |
| Normalized Diluted EPS | 34.78% | 37.57% | 41.33% | 25.37% | 17.01% |
| Average Basic Shares Outstanding | 5.49% | 6.29% | 7.36% | 8.63% | 11.93% |
| Average Diluted Shares Outstanding | 5.49% | 6.29% | 7.36% | 8.63% | 11.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |